Product Pathways - Jak/Stat Pathway

Phospho-Stat3 (Tyr705) Antibody #9131

• pathway
• more info
• application references
• datasheet PDF
• MSDS PDF
• protocols

Applications	Reactivity	MW (kDa)	Source
W IP IF-IC	H M R C (B)	79, 86	Rabbit

Applications Key:  W=Western Blotting  IP=Immunoprecipitation  IF-IC=Immunofluorescence (Immunocytochemistry)
Reactivity Key:  H=Human  M=Mouse  R=Rat  C=Chicken  B=Bovine
Species enclosed in parentheses are predicted to react based on 100% sequence homology. Species cross-reactivity is determined by Western blot.

Specificity / Sensitivity

Phospho-Stat3 (Tyr705) Antibody detects endogenous levels of Stat3 only when phosphorylated at Tyr705. The antibody does not cross-react with other Stat proteins when phosphorylated on the corresponding tyrosine residue, but does cross-react with EGFR.

Source / Purification

Polyclonal antibodies are produced by immunizing rabbits with a synthetic phospho-peptide (KLH-coupled) corresponding to residues surrounding Tyr705 of mouse Stat3. Antibodies are purified by protein A and peptide affinity chromatography.

Background

The Stat3 transcription factor is an important signaling molecule for many cytokines and growth-factor receptors (1) and is required for murine fetal development (2). Stat3 is constitutively activated in a number of human tumors (3,4) and possesses oncogenic potential (5) and anti-apoptotic activities (3). Stat3 is activated by phosphorylation at Tyr705, which induces dimerization, nuclear translocation and DNA binding (6,7). Transcriptional activation seems to be regulated by phosphorylation at Ser727 through the MAPK or mTOR pathways (8,9). Stat3 isoform expression appears to reflect biological function as the relative expression levels of Stat3α (86 kDa) and Stat3β (79 kDa) depend on cell type, ligand exposure or cell maturation stage (10). It is notable that Stat3β lacks the serine phosphorylation site within the carboxy-terminal transcriptional activation domain (8).

1. Heim, M.H. (1999) J. Recept. Signal Transduct. Res. 19, 75-120.
2. Takeda, K. et al. (1997) Proc. Natl. Acad. Sci. USA 94, 3801-3804.
3. Catlett-Falcone, R. et al. (1999) Immunity 10, 105-115.
4. Garcia, R. and Jove, R. (1998) J. Biomed. Sci. 5, 79-85.
5. Bromberg, J.F. et al. (1999) Cell 98, 295-303.
6. Darnell Jr., J.E. et al. (1994) Science 264, 1415-1421.
7. Ihle, J.N. (1995) Nature 377, 591-594.
8. Wen, Z. et al. (1995) Cell 82, 241-250.
9. Yokogami, K. et al. (2000) Curr. Biol. 10, 47-50.
10. Biethahn, S. et al. (1999) Exp. Hematol. 27, 885-894.

Application References

• Bartoli, M. et al. (2000) Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J. Biol. Chem. 275, 33189-33192. This article references the use of Phospho-Stat3 (Tyr705) Antibody in the following applications: IC-IF Western Blotting
• Campbell, C. L. et al. (2001) Increased expression of the interleukin-11 receptor and evidence of STAT3 activation of prostate carcinoma. Am. J. Path. 158, 25-32. This article references the use of Phospho-Stat3 (Tyr705) Antibody in the following applications: Western Blotting
• Mitsui, K. et al. (2003) The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113, 631-642. This article references the use of Phospho-Stat3 (Tyr705) Antibody in the following applications: Western Blotting
• Guo, Z. et al. (2004) CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. Nat. Med. 10, 374-381. This article references the use of Phospho-Stat3 (Tyr705) Antibody in the following applications: IC-IF Western Blotting
• Butzkueven, H. et al. (2002) LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat. Med. 8, 613-619. This article references the use of Phospho-Stat3 (Tyr705) Antibody in the following applications: IHC-FL (floating/frozen) Western Blotting
• Bild, A. H. et al. (2002) Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J. 21, 3255-3263. This article references the use of Phospho-Stat3 (Tyr705) Antibody in the following applications: Western Blotting
• Ducy, P. et al. (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100, 197-207. This article references the use of Phospho-Stat3 (Tyr705) Antibody in the following applications: Western Blotting
• Fujimoto, M. et al. (2000) Defective thymocyte development and perturbed homeostasis of T cells in STAT-induced STAT inhibitor-1/suppressors of cytokine signaling-1 transgenic mice. J. Immunol. 165, 1799-1806. This article references the use of Phospho-Stat3 (Tyr705) Antibody in the following applications: Western Blotting
• Hideshima, T. et al. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071-3076. This article references the use of Phospho-Stat3 (Tyr705) Antibody in the following applications: Western Blotting

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

• 9130 PhosphoPlus® Stat3 (Tyr705) Antibody Kit
• 9132 Stat3 Antibody
• 9133 Stat3 Control Cell Extracts
• 7074 Anti-rabbit IgG, HRP-linked Antibody
• 7720 Prestained Protein Marker, Broad Range (Premixed Format)
• 7727 Biotinylated Protein Ladder Detection Pack
• 7003 20X LumiGLO^® Reagent and 20X Peroxide
• 9138 Phospho-Stat3 (Tyr705) (3E2) Mouse mAb
• 9145 Phospho-Stat3 (Tyr705) (D3A7) Rabbit mAb